NCT03825809

Brief Summary

This is a randomized, single blinded, standard of care controlled clinical trial. This project aims to compare postoperative pain control in patients in two treatment arms of rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard of care control group given standard opioid pain control regimen

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 22, 2019

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 27, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 31, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2020

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2020

Completed
Last Updated

January 31, 2019

Status Verified

January 1, 2019

Enrollment Period

12 months

First QC Date

January 27, 2019

Last Update Submit

January 30, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Pain Levels

    Patients recorded pain levels 3 times per day using Visual analog scales until study completion. Average daily pain was calculated for each patient. Higher values portend worse control.

    10 days post-operatively

  • Patient-Reported Outcomes Measurement Information System

    Patient-Reported Outcomes Measurement Information System Physical Interference (PROMIS PI) nightly until study completion. Average PROMIS PI values calculated nightly. A higher score indicates more pain interference.

    10 days post-operatively

Study Arms (2)

Post-Operative Non Opioid Pain Protocol

EXPERIMENTAL

Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam

Drug: CelecoxibDrug: KetorolacDrug: GabapentinDrug: AcetaminophenDrug: Diazepam

Post-Operative Traditional Pain Protocol

ACTIVE COMPARATOR

Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325

Drug: Hydrocodone-Acetaminophen

Interventions

Post-Operative Non Opioid Pain Protocol

Also known as: Celebrex
Post-Operative Non Opioid Pain Protocol

Traditionally used narcotic pain protocol

Also known as: Norco
Post-Operative Traditional Pain Protocol

Post-Operative Non Opioid Pain Protocol

Also known as: Toradol
Post-Operative Non Opioid Pain Protocol

Post-Operative Non Opioid Pain Protocol

Also known as: Neurontin
Post-Operative Non Opioid Pain Protocol

Post-Operative Non Opioid Pain Protocol

Also known as: Tylenol
Post-Operative Non Opioid Pain Protocol

Post-Operative Non Opioid Pain Protocol

Also known as: Valium
Post-Operative Non Opioid Pain Protocol

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All adult patients over age 18 and scheduled for a primary or revision labral surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Henry Ford Health System

Detroit, Michigan, 48202, United States

RECRUITING

MeSH Terms

Interventions

Celecoxiboxycodone-acetaminophenKetorolacKetorolac TromethamineGabapentinAcetaminophenDiazepam

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur CompoundsPyrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndomethacinIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingAminesgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicAmino AcidsAmino Acids, Peptides, and ProteinsAcetanilidesAnilidesAniline CompoundsBenzodiazepinonesBenzodiazepinesBenzazepines

Study Officials

  • Toufic R Jildeh, MD

    Henry Ford Health System

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Toufic R Jildeh, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident Investigator

Study Record Dates

First Submitted

January 27, 2019

First Posted

January 31, 2019

Study Start

January 22, 2019

Primary Completion

January 20, 2020

Study Completion

May 20, 2020

Last Updated

January 31, 2019

Record last verified: 2019-01

Locations